MENLO PARK, Calif.— November 10, 2021— Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced that the Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) authorizing the Company to conduct a clinical study to assess the safety and effectiveness of a new, higher volume (21 microliters of viscoelastic fluid dispensed), investigational OMNI® device (“higher volume OMNI”) to perform canal viscodilation alone to lower intraocular pressure (IOP) in adults with primary open-angle glaucoma (POAG).
The PRECISION clinical trial is designed as a three-armed randomized controlled trial (RCT), which the Company believes will be the first of its kind and represents the largest MIGS clinical trial ever…